Claire Snyder

Claire Snyder

Auto-generated profile, based on publicly available information

Claire Snyder

Johns Hopkins University School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2018 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
PPPro Data Presentation Delphi Panel
Pro Data Presentation Delphi Panel
CSClaire Snyder
Claire Snyder
KSKatherine Smith
Katherine Smith
BHBernhard Holzner
Bernhard Holzner
YRYonaira M. Rivera
Yonaira M. Rivera
MBMichael Brundage
Michael Brundage

13 January 2017 in Cancer
Verified
Journal Article
Open access
PDF file
CSClaire F. Snyder
Claire F. Snyder
KSKatherine C. Smith
Katherine C. Smith
EBElissa T. Bantug
Elissa T. Bantug
ETElliott E. Tolbert
Elliott E. Tolbert
ABAmanda L. Blackford
Amanda L. Blackford
TBThe Pro Data Presentation Stakeholder Advisory Board
The Pro Data Presentation Stakeholder Advisory Board
BACKGROUND: Patient‐reported outcomes (PROs) (eg, symptoms, functioning) can inform patient management. However, patients and clinicians often have difficulty interpreting score meaning. The authors tested approaches for presenting PRO data to improve interpretability.METHODS: This mixed‐methods study included an Internet survey of cancer patients/survivors, oncology clinicians, and PRO researchers circulated via snowball sampling, plus individual in‐person interviews. Clinical importance was conveyed using 3 approaches (presented in random order): normal score range shaded green, concerning scores circled in red, and red threshold lines indicating normal versus concerning scores. Versions also tested 2 approaches to score directionality: higher = more (better for function, worse for symptoms) and higher = better for both function and symptoms. Qualitative data from online comments and in‐person interviews supplemented quantitative results on interpretation accuracy, clarity, and the “most useful” format.RESULTS: The survey included 1113 respondents: 627 survivors, 236 clinicians, and 250 researchers, plus 10 patients and 10 clinicians who were purposively sampled interviewees. Interpretation accuracy ranged from 53% to 100%. The formats in which higher = better were interpreted more accurately versus those in which higher = more (odds ratio [OR], 1.30; 95% confidence interval [CI], 1.07‐1.58) and were more likely to be rated “very”/“somewhat” clear (OR, 1.39; 95% CI, 1.13‐1.70) and “very” clear (OR, 1.36; 95% CI, 1.18‐1.58). Red circle formats were interpreted more accurately than green‐shaded formats when the first format presented (OR, 1.29; 95% CI, 1.00‐1.65). Threshold‐line formats were more likely to be rated “very” clear than green‐shaded (OR, 1.43; 95% CI, 1.19‐1.71) and red‐circled (OR, 1.22, 95% CI, 1.02‐1.46) formats. Threshold lines were most often selected as “most useful.”CONCLUSIONS: The current results support presenting PRO data with higher = better directionality and threshold lines indicating normal versus concerning scores. Cancer 2017;123:1848–1859. © 2017 The Authors. Cancer published byWiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations aremade.

15 November 2014 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
CSClaire F. Snyder
Claire F. Snyder
ABAmanda L. Blackford
Amanda L. Blackford
JSJonathan Sussman
Jonathan Sussman
DBDaryl Bainbridge
Daryl Bainbridge
Doris HowellDoris Howell
Doris Howell
AWAlbert W. Wu
Albert W. Wu

26 February 2015 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
CSClaire F. Snyder
Claire F. Snyder
KFKevin D. Frick
Kevin D. Frick
RHRobert J. Herbert
Robert J. Herbert
ABAmanda L. Blackford
Amanda L. Blackford
BNBridget A. Neville
Bridget A. Neville
CECraig C. Earle
Craig C. Earle

1 May 2019 in Medical Care
Verified
Journal Article
Closed access
CSClaire Snyder
Claire Snyder
MBMichael Md Brundage
Michael Md Brundage
YRYonaira M. Rivera
Yonaira M. Rivera
AWAlbert W. Wu
Albert W. Wu
Patients are increasingly being asked to complete standardized, validated questionnaires with regard to their symptoms, functioning, and well-being [ie, patient-reported outcomes (PROs)] as part of routine care. These PROs can be used to inform patients’ care and management, which we refer to as “PRO-cision Medicine.” For PRO-cision Medicine to be most effective, clinicians and patients need to be able to understand what the PRO scores mean and how to act on the PRO results. The papers in this supplement to Medical Care describe various methods that have been used to address these issues. Specifically, the supplement includes 14 papers: 6 describe different methods for interpreting PROs and 8 describe how different PRO systems have addressed interpreting PRO scores and/or acting on PRO results. As such, this “Methods Toolkit” can inform clinicians and researchers aiming to implement routine PRO reporting into clinical practice by providing methodological fundamentals and real-world examples to promote personalized patient care.

22 August 2018 in Medical Decision Making
Verified
Journal Article
Closed access
ETElliott Tolbert
Elliott Tolbert
MBMichael Brundage
Michael Brundage
EBElissa Bantug
Elissa Bantug
ABAmanda Blackford
Amanda Blackford
KSKatherine Smith
Katherine Smith
PBPro Data Presentation Stakeholder Advisory Board
Pro Data Presentation Stakeholder Advisory Board
Background. Patient-reported outcome (PRO) results from clinical trials and research studies can inform patient-clinician decision making. However, data presentation issues specific to PROs, such as scaling directionality (higher scores may represent better or worse outcomes) and scoring strategies (normed v. nonnormed scores), can make the interpretation of PRO scores uniquely challenging. Objective. To identify the association of PRO score directionality, score norming, and other factors on a) how accurately PRO scores are interpreted and b) how clearly they are rated by patients, clinicians, and PRO researchers. Methods. We electronically surveyed adult cancer patients/survivors, oncology clinicians, and PRO researchers and conducted one-on-one cognitive interviews with patients/survivors and clinicians. Participants were randomized to 1 of 3 line graph formats showing longitudinal change: higher scores indicating “better,” “more” (better for function, worse for symptoms), or “normed” to a population average. Quantitative data evaluated interpretation accuracy and clarity. Online survey comments and cognitive interviews were analyzed qualitatively. Results. The Internet sample included 629 patients, 139 clinicians, and 249 researchers; 10 patients and 5 clinicians completed cognitive interviews. “Normed” line graphs were less accurately interpreted than “more” (odds ratio [OR] = 0.76; P = 0.04). “Better” line graphs were more accurately interpreted than both “more” (OR = 1.43; P = 0.01) and “normed” (OR = 1.88; P = 0.04). “Better” line graphs were more likely to be rated clear than “more” (OR = 1.51; P = 0.05). Qualitative data informed interpretation of these findings. Limitations. The survey relied on the online platforms used for distribution and consequent snowball sampling. We do not have information regarding participants’ numeracy/graph literacy. Conclusions. For communicating PROs as line graphs in patient educational materials and decision aids, these results support using graphs, with higher scores consistently indicating better outcomes.